12/6
05:30 pm
tcrx
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
Medium
Report
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
12/3
06:31 pm
tcrx
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities [Yahoo! Finance]
Medium
Report
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities [Yahoo! Finance]
12/3
04:05 pm
tcrx
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
Medium
Report
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
11/14
10:53 am
tcrx
TScan Therapeutics (NASDAQ:TCRX) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.
Low
Report
TScan Therapeutics (NASDAQ:TCRX) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.
11/13
08:11 am
tcrx
TScan Therapeutics (NASDAQ:TCRX) had its price target lowered by analysts at HC Wainwright from $10.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
TScan Therapeutics (NASDAQ:TCRX) had its price target lowered by analysts at HC Wainwright from $10.00 to $7.00. They now have a "buy" rating on the stock.
11/12
07:00 am
tcrx
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/5
07:00 am
tcrx
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Low
Report
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
11/4
08:09 am
tcrx
TScan Therapeutics (NASDAQ:TCRX) had its price target lowered by analysts at Needham & Company LLC from $9.00 to $6.00. They now have a "buy" rating on the stock.
Medium
Report
TScan Therapeutics (NASDAQ:TCRX) had its price target lowered by analysts at Needham & Company LLC from $9.00 to $6.00. They now have a "buy" rating on the stock.
11/4
07:03 am
tcrx
TScan Therapeutics (NASDAQ:TCRX) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.
Medium
Report
TScan Therapeutics (NASDAQ:TCRX) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.
11/3
06:30 am
tcrx
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
High
Report
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
10/25
12:13 pm
tcrx
TScan Therapeutics (NASDAQ:TCRX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TScan Therapeutics (NASDAQ:TCRX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.